Holen Sie sich die Stockscreener-App
0.992
4.67%
-0.048
Schlusskurs vom Vortag:
$1.04
Offen:
$1.03
24-Stunden-Volumen:
1.19M
Relative Volume:
1.20
Marktkapitalisierung:
$106.25M
Einnahmen:
$33.03M
Nettoeinkommen (Verlust:
$-44.63M
KGV:
-2.3658
EPS:
-0.4193
Netto-Cashflow:
$-36.18M
1W Leistung:
-4.67%
1M Leistung:
+14.85%
6M Leistung:
-43.35%
1J Leistung:
-54.73%
1-Tages-Spanne:
$0.97
$1.03
1-Wochen-Bereich:
$0.97
$1.105
52-Wochen-Spanne:
$0.6434
$2.40
Maxcyte Inc Stock (MXCT) Company Profile
Firmenname
Maxcyte Inc
Sektor
Branche
Telefon
301-517-5556
Adresse
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
0.9919 | 111.41M | 33.03M | -44.63M | -36.18M | -0.4193 |
ABT
Abbott Laboratories
|
86.67 | 152.25B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
312.11 | 121.33B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.83 | 100.91B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.81 | 85.88B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.73 | 49.39B | 6.30B | 1.07B | 1.09B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-08-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Eingeleitet | Stephens | Overweight |
| 2023-11-29 | Eingeleitet | Craig Hallum | Buy |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | BTIG Research | Buy |
| 2021-08-24 | Eingeleitet | Cowen | Outperform |
| 2021-08-24 | Eingeleitet | Stephens | Overweight |
| 2021-08-24 | Eingeleitet | Stifel | Buy |
| 2021-08-24 | Eingeleitet | Wedbush | Outperform |
| 2021-08-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Maxcyte Inc Aktie (MXCT) Neueste Nachrichten
MaxCyte outlines $30M-$32M 2026 revenue outlook as board authorizes $10M share repurchase program - MSN
MaxCyte Inc. (MXCT) Struggles Near Support as Selling Pressure PersistsFree Signal Network - Newser
MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock DeclinesSegment Revenue Breakdown - Newser
MaxCyte Inc stock (US57777K1060): cell-therapy enabler after recent earnings update - AD HOC NEWS
MaxCyte, Inc. (MXCT) reports Q1 loss, tops revenue estimates - MSN
MaxCyte Inc stock (US57777K1060): recent volatility and growth hopes in cell therapy tools - AD HOC NEWS
MaxCyte Q1 earnings call highlights - MSN
What MaxCyte (MXCT)'s -4.59% Decline Means for Investors 2026-05-15Stock Idea Sharing Hub - newser.com
MaxCyte (MXCT) Reports Strong Q1 2026 — Revenue $N/A, EPS BeatsExpert Entry Points - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail
River Global Investors Discloses Investment in MaxCyte with 6.1% Stake - TradingView
River Global Investors builds 6.1% MaxCyte (MXCT) position with 6.53M shares - Stock Titan
Stock Market Today: Dow Jones Futures Fall, S&P 500 Gains As Trump Takes Big Tech Leaders To China—Nvidia, Nextpower, Red Cat In Focus - Sahm
Cisco, Alibaba And 3 Stocks To Watch Heading Into Wednesday - Sahm
MaxCyte (MXCT) EPS Loss Narrows In Q1 2026 Challenging Bearish Profitability Narratives - Sahm
MSN Money - MSN
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue dips as expenses fall - Stock Titan
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $4 - Moomoo
BTIG Maintains MaxCyte(MXCT.US) With Hold Rating - Moomoo
MaxCyte posts $4.8M loss, still lines up $10M stock buyback - Stock Titan
Stock Market Today: Dow Jones Futures Fall, Nasdaq Gains As Trump Takes Big Tech Leaders To China— Nvidia, Nextpower, Red Cat In Focus (UPDATED) - Benzinga
MaxCyte, Inc. (NASDAQ:MXCT) Q1 2026 Earnings Call Transcript - Insider Monkey
Minot Light Capital Partners Q1 2026 Investor Letter - HarianBasis.co
Here’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investors - Insider Monkey
Earnings Call Summary | MaxCyte(MXCT.US) Q1 2026 Earnings Conference - Moomoo
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - The Manila Times
MaxCyte Q1 Earnings Call Highlights - sharewise.com
MaxCyte, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue By Investing.com - Investing.com South Africa
Earnings call transcript: MaxCyte beats Q1 2026 forecasts with strong revenue - Investing.com Nigeria
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
MaxCyte Reports Q1 2026 Results, Launches Share Buyback - TipRanks
MaxCyte (NASDAQ:MXCT) Q1 2026 Results Beat Estimates, Stock Rises on Buyback - ChartMill
MaxCyte (NASDAQ: MXCT) Q1 2026 revenue $9.7M as board approves $10M buyback - Stock Titan
Press Release: MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance - Moomoo
MaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ... By GuruFocus - Investing.com Canada
MaxCyte (MXCT) price target decreased by 11.67% to 4.33 - MSN
BTIG Downgrades MaxCyte (MXCT) - MSN
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026 - The Manila Times
MaxCyte (MXCT) price target decreased by 14.88% to 4.90 - MSN
Finanzdaten der Maxcyte Inc-Aktie (MXCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Maxcyte Inc-Aktie (MXCT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hemrajani Rekha | Director |
Jun 25 '25 |
Sale |
2.09 |
10,684 |
22,378 |
39,893 |
| Swirsky Douglas J | CHIEF FINANCIAL OFFICER |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
161,811 |
| Masoud Maher | President and CEO |
Aug 13 '25 |
Buy |
1.37 |
75,000 |
102,915 |
175,000 |
| Erck Stanley C | Director |
Aug 13 '25 |
Buy |
1.37 |
100,000 |
137,220 |
398,328 |
| DOUGLAS RICHARD | Director |
Aug 13 '25 |
Buy |
1.39 |
80,000 |
111,040 |
230,577 |
| Brooke William W | Director |
Aug 13 '25 |
Buy |
1.29 |
50,000 |
64,500 |
150,879 |
0.32%
0.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):